US › Healthcare

AC Immune Ltd (ACIU)

US · Healthcare · Biotechnology

$2.39-2.45%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$15.1M

Revenue YoY

+1057.2%

Net profit

$1.9M

EPS

$0.03

EPS estimate

$-0.22

Net margin

12.4%

EPS came in at 0.03 against a street estimate of -0.22 — a beat of 113.6%.

Key statistics

Market cap

$237.6M

Forward P/E

16.6

P/B

6.57

Book value

$0.43

EPS (TTM)

$-0.54

52-week high

$4.00

52-week low

$2.10

50-day MA

$2.64

200-day MA

$2.78

Beta

1.55

Analyst view

Analysts rate AC Immune Ltd a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $8.55.

Shareholding

Insiders

38.09%

Institutions

24.43%

Largest institutional holders

Fund	Stake
Bvf Inc	19.94%
Wells Fargo & Co	1.01%
Renaissance Technologies Corp	0.84%
Millennium Management LLC	0.78%
BlackRock Inc	0.52%
Dimensional Fund Advisors, Inc.	0.34%
Arrowstreet Capital Limited Partnership	0.23%
Citadel Advisors Llc	0.21%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for AC Immune Ltd — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.